ANAB · long Anaptysbio INC
AnaptysBio is pitched for a 50% to 80% return over four to six weeks after its April 2026 taxable spin-off of R&D-heavy operations.
NASDAQ
Anaptysbio, INC
ANAB
9 stories
$1.4B Market cap · 2026-10-21
ANAB · long Laughing Water Capital on X
@CFAs4CFPs @BATMongoose it was disclosed at trial that GSK tried to buy $ANAB 3 times over the last year. IMHO this is more important than whatever odds I put on the trial outcome. It seems that in all scenarios ANAB gets sold. If they win trial, the $ will be higher. If they dont it will still be fine
Laughing Water Capital on X
@FriendlyCapMgmt @thecontracap there have been some things i view as negative for $ANAB and some that are positive. but in my view in order to make this investment you have to focus on the future cashflows, not the trial.
Laughing Water Capital on X
@thecontracap also worth noting that if $ANAB loses, maybe the stock goes down but future cash flows do not. Plan B is prob just sell the royalty stream, which is why the former CFO of $RPRX was added to the BOD 4 months ago. Heads win a ton. Tails you don't lose (if you can handle the vol)
Laughing Water Capital on X
@thecontracap agree ex-CEO statements are not +. However, statements from the GSK manager responsible for managing the $ANAB collaboration make it clear he thought GSK was in violation of the agreement. Not good for either side. Think sanctity of contract law has to come above all else though
Laughing Water Capital on X
@thecontracap 2/x)on the other hand, if $ANAB's position is upheld, it sucks for GSK, but contract law as a whole in DE continues to successfully govern the land as it has for centuries prior. Not clear to me that AI can consider the gravity of dismantling all of DE contract law...
Laughing Water Capital on X
@thecontracap 1/x)$ANAB also not a lawyer but seems to me that the implications of GSK's position would be catastrophic for contract law in DE if supported by the court. Effectively, any acquiror could disavow the obligations of a purchased subsidiary. Which seems "absurd" in the legal sense.
Laughing Water Capital on X
Grt🧵on $GSK's cancer biz. But IMHO GSK cant max their ROI b/c $ANAB can block GSK from partnering w/ other PD1s like $MRK's Keytruda. Trial is 7/14 & GSK could lose 100% of JEMPERLI which IMHO is ~10% of GSK's mkt cap. I think GSK settles or buys ANAB for big $$$. Disc: Long https://t.co/N4Rls7h63Z https://t.co/04Zx6UdUwi
AnaptysBio (ANAB)
AnaptysBio’s Jemperli royalty receipts rise after a Sagard financing obligation ends in 2027.
Investor Letters
Letters that discuss ANAB.
- Greenhaven Road Capital Main Fund Q2 second quarter 2026 ANAB $1.4BBUR $680MCLBT $2.9B
- Laughing Water Capital H1 2026 Q2 of 2026 ANAB $1.4BGSK $99BLFCR $242M
- Summers Value Partners Q2 2026 Letter second quarter of 2026 CCSI $656M
Tickers on this page
Companies the stories above are also about, besides ANAB.
